SG10202006685XA - Treatment of Cancers Using Anti-NKG2A Agents - Google Patents

Treatment of Cancers Using Anti-NKG2A Agents

Info

Publication number
SG10202006685XA
SG10202006685XA SG10202006685XA SG10202006685XA SG10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA
Authority
SG
Singapore
Prior art keywords
cancers
treatment
nkg2a
agents
nkg2a agents
Prior art date
Application number
SG10202006685XA
Inventor
Pascale Andre
Mathieu Blery
Caroline Soulas
Nicolaï Wagtmann
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of SG10202006685XA publication Critical patent/SG10202006685XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10202006685XA 2014-10-23 2015-10-23 Treatment of Cancers Using Anti-NKG2A Agents SG10202006685XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462067642P 2014-10-23 2014-10-23

Publications (1)

Publication Number Publication Date
SG10202006685XA true SG10202006685XA (en) 2020-08-28

Family

ID=54347541

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202006685XA SG10202006685XA (en) 2014-10-23 2015-10-23 Treatment of Cancers Using Anti-NKG2A Agents
SG11201701388UA SG11201701388UA (en) 2014-10-23 2015-10-23 Treatment of cancers using anti-nkg2a agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701388UA SG11201701388UA (en) 2014-10-23 2015-10-23 Treatment of cancers using anti-nkg2a agents

Country Status (11)

Country Link
US (2) US10329348B2 (en)
EP (2) EP3209687A1 (en)
JP (1) JP6889660B2 (en)
KR (1) KR102598068B1 (en)
CN (1) CN107073116A (en)
AU (1) AU2015334886B9 (en)
CA (1) CA2959841A1 (en)
IL (1) IL250677B (en)
RU (1) RU2721271C2 (en)
SG (2) SG10202006685XA (en)
WO (1) WO2016062851A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107496917B (en) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 Compositions comprising stable antibodies
EP2721068B1 (en) 2011-06-17 2018-12-05 Novo Nordisk A/S Selective elimination of erosive cells
MX2017003303A (en) 2014-09-16 2017-08-04 Innate Pharma Neutralization of inhibitory pathways in lymphocytes.
KR20170068458A (en) 2014-09-16 2017-06-19 이나뜨 파르마, 에스.아. Treatment regimens using anti-nkg2a antibodies
CA2959841A1 (en) 2014-10-23 2016-04-28 Innate Pharma Treatment of cancers using anti-nkg2a agents
EP3325967B1 (en) 2015-07-24 2019-12-04 Innate Pharma Methods for detecting tissue infiltrating nk cells
EP3868787A1 (en) 2016-01-21 2021-08-25 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
DE102017001875A1 (en) * 2017-02-27 2018-08-30 Wolfgang Würfel Drug for malignant treatment
DE102017005815A1 (en) * 2017-06-20 2018-12-20 Wolfgang Würfel Vaccine for the treatment of a malignancy
EP3652207A1 (en) * 2017-07-10 2020-05-20 Innate Pharma Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer
WO2019165307A1 (en) * 2018-02-23 2019-08-29 Abexxa Biologics, Inc. Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
US11464840B2 (en) 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers
TW202003582A (en) * 2018-03-13 2020-01-16 法商天賜製藥公司 Treatment of head and neck cancer
WO2020023548A1 (en) * 2018-07-23 2020-01-30 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
WO2020094071A1 (en) * 2018-11-07 2020-05-14 上海怀越生物科技有限公司 Nkg2a antibody, preparation method therefor and application thereof
TW202033555A (en) 2018-11-16 2020-09-16 美商必治妥美雅史谷比公司 Anti-nkg2a antibodies and uses thereof
EP4045535A1 (en) * 2019-10-14 2022-08-24 Innate Pharma Treatment of cancer with ilt-2 inhibitors
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981997B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
EP4347651A1 (en) * 2021-06-01 2024-04-10 Les Laboratoires Servier Anti-nkg2a antibodies and compositions

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US122637A (en) 1872-01-09 Improvement in vapor-burners
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
EP0586002B1 (en) 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
IT1277827B1 (en) 1995-03-01 1997-11-12 Ministero Uni Ricerca Scient E CHIMERIC MURINE/HUMAN MONOCLONAL ANTIBODY OR ITS FRAGMENT SPECIFIC FOR THE EGF RECEPTOR (EGF-R)
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
DK2180007T4 (en) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity
MXPA01007170A (en) 1999-01-15 2002-07-30 Genentech Inc Polypeptide variants with altered effector function.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6794494B1 (en) 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
KR100480985B1 (en) 2000-05-19 2005-04-07 이수화학 주식회사 Humanized antibodies to the epidermal growth factor receptor
US7132511B2 (en) 2001-02-19 2006-11-07 Merck Patent Gmbh Modified anti-EGFR antibodies with reduced immunogenicity
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
ATE446317T1 (en) 2001-05-11 2009-11-15 Ludwig Inst For Cancer Res Ltd SPECIFIC BINDING PROTEINS AND THEIR USE
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
MXPA03011365A (en) 2001-06-13 2005-03-07 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr).
WO2003014159A1 (en) 2001-08-03 2003-02-20 Commonwealth Scientific And Industrial Research Organisation Methods of screening based on the egf receptor crystal structure
AU2002326531A1 (en) 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
BR0213761A (en) 2001-10-25 2005-04-12 Genentech Inc Compositions, pharmaceutical preparation, industrialized article, mammalian treatment method, host cell, method for producing a glycoprotein and use of the composition
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7351803B2 (en) 2002-05-30 2008-04-01 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
ATE536188T1 (en) 2002-08-14 2011-12-15 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
JP2004126818A (en) 2002-09-30 2004-04-22 Toshiba Corp Electronic equipment system, battery unit, and operation control method for battery unit
US20050058661A1 (en) 2002-10-18 2005-03-17 Sykes Kathryn F. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus Borrelia
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP3803790B2 (en) 2003-02-17 2006-08-02 株式会社東北テクノアーチ Novel diabody-type bispecific antibody
EP1638606B1 (en) 2003-06-27 2016-01-06 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US20050142133A1 (en) 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
WO2005115452A2 (en) 2004-04-16 2005-12-08 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
EP1761563A4 (en) 2004-05-10 2008-05-14 Macrogenics Inc HUMANIZED Fc gamma RIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
CA2591059C (en) 2004-12-28 2018-11-06 Innate Pharma Monoclonal antibodies against nkg2a
KR101569300B1 (en) 2005-02-07 2015-11-13 로슈 글리카트 아게 Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
JP2008541770A (en) 2005-06-03 2008-11-27 ジェネンテック・インコーポレーテッド Methods for producing antibodies having altered fucosylation levels
EP2573114B1 (en) 2005-08-10 2016-03-30 MacroGenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2009529331A (en) 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド Identification and engineering modification of antibodies having mutated heavy chains and methods of use thereof
WO2008105886A2 (en) 2006-05-26 2008-09-04 Macrogenics, Inc. HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
JP5368301B2 (en) 2006-06-22 2013-12-18 ノボ・ノルデイスク・エー／エス Soluble heterodimeric receptor and uses thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
BRPI0712953B8 (en) * 2006-06-30 2021-05-25 Novo Nordisk As anti-nkg2a antibodies, their use, and pharmaceutical composition
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
CN101952317B (en) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 Humanized anti-human NKG2A monoclonal antibody
WO2010112413A1 (en) 2009-03-31 2010-10-07 Roche Glycart Ag Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
CN107496917B (en) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 Compositions comprising stable antibodies
LT2542256T (en) 2010-03-04 2019-10-25 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2721068B1 (en) 2011-06-17 2018-12-05 Novo Nordisk A/S Selective elimination of erosive cells
US20170253658A1 (en) 2014-08-28 2017-09-07 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
KR20170068458A (en) 2014-09-16 2017-06-19 이나뜨 파르마, 에스.아. Treatment regimens using anti-nkg2a antibodies
MX2017003303A (en) 2014-09-16 2017-08-04 Innate Pharma Neutralization of inhibitory pathways in lymphocytes.
CA2959841A1 (en) 2014-10-23 2016-04-28 Innate Pharma Treatment of cancers using anti-nkg2a agents
EP3868787A1 (en) 2016-01-21 2021-08-25 Innate Pharma Neutralization of inhibitory pathways in lymphocytes

Also Published As

Publication number Publication date
CN107073116A (en) 2017-08-18
AU2015334886B2 (en) 2021-06-10
SG11201701388UA (en) 2017-03-30
US20170313773A1 (en) 2017-11-02
WO2016062851A1 (en) 2016-04-28
US10329348B2 (en) 2019-06-25
KR20170070076A (en) 2017-06-21
RU2721271C2 (en) 2020-05-18
US11225519B2 (en) 2022-01-18
KR102598068B1 (en) 2023-11-06
AU2015334886B9 (en) 2021-07-08
RU2017107559A3 (en) 2019-04-15
CA2959841A1 (en) 2016-04-28
AU2015334886A1 (en) 2017-03-16
RU2017107559A (en) 2018-11-27
JP6889660B2 (en) 2021-06-18
JP2017537069A (en) 2017-12-14
EP3659625A1 (en) 2020-06-03
EP3209687A1 (en) 2017-08-30
IL250677B (en) 2021-03-25
US20190322744A1 (en) 2019-10-24
IL250677A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
IL250677B (en) Treatment of cancers using anti-nkg2a agents
IL259783A (en) Methods of treatment of malignancies
GB201701673D0 (en) Methods of well treatment
FI3851537T3 (en) Treatment of hyperbilirubinemia
SI3122358T1 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
IL247267A0 (en) Improved methods for the treatment of vascularizing cancers
HK1231561A1 (en) Cancer treatment
IL263835A (en) Exosome-guided treatment of cancer
GB201416832D0 (en) Methods of treatment
GB201408297D0 (en) Treatment of cancer
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201411027D0 (en) Treatment
GB201417456D0 (en) Treatment of cancer
GB201512139D0 (en) Methods of treatment
GB201407837D0 (en) Methods of cancer therapy
GB201622214D0 (en) treatment of cancer
GB201417465D0 (en) Treatment of cancers
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer
GB201409362D0 (en) Treatment of cancer
PT3851537T (en) Treatment of hyperbilirubinemia
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer